On Monday the European Commission informed Teva Pharmaceutical of its preliminary findings that the company breached EU antitrust rules with practices aimed at delaying competition to multiple sclerosis product Copaxone.
The Commission first carried out unannounced inspections at the premises of several Teva subsidiaries in October 2019 and in March 2021 initiated an investigation over its practices relating to Copaxone, reported Reuters.
“There is not yet a treatment for the chronic illness of multiple sclerosis, so innovative medicines can make a major difference to patients’ quality of life,” the Commission’s competition policy head Margrethe Vestager said on Monday.
“Effective protection of intellectual property is key to this scientific progress. Our concern is that Teva may have misused the patent system to shield itself from competition.”
If the European Commission’s preliminary views are confirmed, Teva’s behavior would infringe Article 102 of the Treaty on the Functioning of the European Union, which prohibits the abuse of a dominant position.
Featured News
Woolworths Calls On ACCC To Conduct a “Fact-Based” Inquiry into Supermarket Competition
May 22, 2024 by
CPI
EU Chips Act Set to Attract Over €100 Billion in Private Investment by 2030
May 22, 2024 by
CPI
Brazil’s Antitrust Regulator Approves New Terms for Petrobras Agreement
May 22, 2024 by
CPI
Apple Challenges €1.84 Billion EU Fine Over App Store Restrictions
May 22, 2024 by
CPI
SEC Urges Lawmakers to Reject New Crypto Bill, Citing Market Risks
May 22, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI